Tamoxifen-Dependent Induction of AGR2 Is Associated with Increased Aggressiveness of Endometrial Cancer Cells.

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Science. Official publication website can be found on muni.cz.

Authors	HRSTKA Roman PODHOREC Ján NENUTIL Rudolf SOMMEROVÁ Lucia OBACZ Joanna Agnieszka ĎURECH Michal FAKTOR Jakub BOUCHAL Pavel SKOUPILOVÁ Hana VOJTĚŠEK Bořivoj
Year of publication	2017
Type	Article in Periodical
Magazine / Source	Cancer Investigation
MU Faculty or unit	Faculty of Science
Citation
Web	http://dx.doi.org/10.1080/07357907.2017.1309546
Doi	http://dx.doi.org/10.1080/07357907.2017.1309546
Keywords	AGR2; Breast cancer; Endometrial cancer; Tamoxifen
Description	Tamoxifen treatment in breast cancer patients is associated with increased risk of endometrial malignancies. Significantly, higher AGR2 expression was found in endometrial cancers that developed in women previously treated with tamoxifen compared to those who had not been exposed to tamoxifen. An association of elevated AGR2 level with myometrial invasion occurrence and invasion depth was also found. In vitro analyses identified a stimulatory effect of AGR2 on cellular proliferation. Although adverse tamoxifen effects on endometrial cells remain elusive, our work identifies elevated AGR2 as a candidate tamoxifen-dependent mechanism of action responsible for increased incidence of endometrial cancer.
Related projects:	Evaluace nových potenciálních cílů a inhibitorů pro blokování vývoje metastáz u luminálních A nádorů prsu